These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 8695873

  • 41. Thrombopoietin and the TPO receptorduring platelet storage.
    Xia Y, Li J, Bertino A, Kuter DJ.
    Transfusion; 2000 Aug; 40(8):976-87. PubMed ID: 10960526
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. c-mpl, the thrombopoietin receptor.
    Vainchenker W, Methia N, Debili N, Titeux M, Wendling F.
    Thromb Haemost; 1995 Jul; 74(1):526-8. PubMed ID: 8578519
    [Abstract] [Full Text] [Related]

  • 48. In vivo effects of Mpl ligand administration and emerging clinical applications for the Mpl ligands.
    Kuter DJ.
    Curr Opin Hematol; 1997 May; 4(3):163-70. PubMed ID: 9209831
    [Abstract] [Full Text] [Related]

  • 49. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
    Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J.
    Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice.
    Akahori H, Ozai M, Ida M, Shibuya K, Kato T, Miyazaki H.
    Ther Apher; 1998 Feb; 2(1):58-64. PubMed ID: 10227790
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers.
    Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, Cheung EN, Terry D, Sheridan W.
    Blood; 2000 Apr 15; 95(8):2514-22. PubMed ID: 10753829
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Recombinant human c-Mpl ligand (thrombopoietin) not only acts on megakaryocyte progenitors, but also on erythroid and multipotential progenitors in vitro.
    Tanimukai S, Kimura T, Sakabe H, Ohmizono Y, Kato T, Miyazaki H, Yamagishi H, Sonoda Y.
    Exp Hematol; 1997 Sep 15; 25(10):1025-33. PubMed ID: 9293899
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
    Basser RL.
    Stem Cells; 1998 Sep 15; 16 Suppl 2():225-9. PubMed ID: 11012194
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.